| Name | Title | Contact Details |
|---|
At PharmMD, we believe every patient deserves personalized attention, the best information available, and reliable guidance from medical professionals to live a healthier life. This deeply held conviction guided our founder Fred McWhorter, an old-fashioned pharmacist who devoted more than 50 years to his passion of bringing health and healing to his customers–not simply selling medicine. Recognizing the value of emerging technology, he envisioned building a real-time information bridge between pharmacists (Pharm) and physicians (MD) to significantly improve patient treatment. Following Fred’s untimely death in 2005, his brother Clayton McWhorter, a veteran healthcare pioneer, brought Fred’s dream to fruition. In 2006, Clayton teamed with entrepreneur Samuel “Bo” Bartholomew to establish PharmMD in Nashville, TN. With the arrival of successful healthcare executive Robert Yeager as CEO in 2013, PharmMD pressed to the forefront in Medicare Part D Star Ratings improvement, as well as Medication Therapy Management (MTM) programs. Today PharmMD remains a leader in quality improvement and a healthcare industry innovator, delivering fast and effective solutions to CMS-regulated health plans and employer groups. Our pioneering technology, proprietary protocols and personalized patient profiles, combined with our outcomes-driven reporting, provide a catalyst for effective medication decisions; ultimately upholding Fred’s vision for improving lives. We exist to create a healthier world through the most effective use of the right medication.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
InSightec is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company`s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world.
APT Pharmaceuticals, Inc is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.